Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 25, 2024 18:43 ET | Source: OnKure, Inc.

OnKure Announces the Appointment of Dylan Hartley as Chief Scientific Officer

BOULDER, Colo., July 25, 2024 (GLOBE NEWSWIRE) -- OnKure, Inc. today announced that Dylan Hartley, Ph.D. has been appointed to the position of Chief Scientific Officer. In this position, Dr. Hartley...
June 19, 2024 17:42 ET | Source: OnKure, Inc.

OnKure Announces the Appointment of Rogan Nunn, J.D., as General Counsel and Secretary

BOULDER, Colo., June 19, 2024 (GLOBE NEWSWIRE) -- OnKure, Inc. today announced the appointment of Rogan Nunn as General Counsel and Secretary. Mr. Nunn will be a member of OnKure’s Executive Team,...
February 15, 2024 09:31 ET | Source: OnKure, Inc.

OnKure Announces the Appointment of Samuel Agresta, M.D., as Chief Medical Officer

BOULDER, Colo., Feb. 15, 2024 (GLOBE NEWSWIRE) -- OnKure, Inc. today announced the appointment of Samuel Agresta, M.D., M.P.H. as Chief Medical Officer. Dr. Agresta brings more than 15 years of...
January 04, 2024 09:00 ET | Source: OnKure, Inc.

OnKure Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for its Mutant Selective PI3Kα inhibitor, OKI-219

BOULDER, Colo., Jan. 04, 2024 (GLOBE NEWSWIRE) -- OnKure, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of OKI-219,...
September 20, 2023 09:41 ET | Source: OnKure, Inc.

OnKure Therapeutics Appoints Ann Howell, Pharm.D., as Vice President of Regulatory Affairs

BOULDER, Colo., Sept. 20, 2023 (GLOBE NEWSWIRE) -- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today...
May 23, 2023 07:00 ET | Source: OnKure, Inc.

OnKure Therapeutics Announces $54 Million Series C Financing

BOULDER, Colorado, May 23, 2023 (GLOBE NEWSWIRE) -- OnKure, Inc. a precision oncology company, today announced that it has successfully closed a $54 million Series C financing. The financing was led...
December 06, 2022 07:00 ET | Source: OnKure, Inc.

OnKure Therapeutics Appoints Robbie Alton, Pharm., as Vice President of Clinical Operations

BOULDER, Colo., Dec. 06, 2022 (GLOBE NEWSWIRE) -- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today...
June 21, 2022 07:00 ET | Source: OnKure, Inc.

OnKure Therapeutics Appoints Kevin S. Litwiler, Ph.D., as Senior Vice President of DMPK and Clinical Pharmacology

BOULDER, Colo., June 21, 2022 (GLOBE NEWSWIRE) -- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today...
June 02, 2022 07:00 ET | Source: OnKure, Inc.

OnKure Therapeutics Announces First Patient Dosed in the Phase 1b/2 Nautilus Trial of OKI-179 in Combination with Binimetinib in Patients with Advanced NRAS-Mutated Melanoma

BOULDER, Colo., June 02, 2022 (GLOBE NEWSWIRE) -- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today...
April 25, 2022 07:00 ET | Source: OnKure, Inc.

OnKure Therapeutics Expands Boulder Footprint with the Opening of a New Research Laboratory

BOULDER, Colo., April 25, 2022 (GLOBE NEWSWIRE) -- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today...